Abstract
This chapter discusses the genetics, metabolic actions, substrates, inducers, and inhibitors of cytochrome P450 2C9.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Kupfer A, Desmond PV, Schenker S, et al. Family study of a genetically determined deficiency of mephenytoin hydroxylation in man [letter]. Pharmacologist. 1979;21:173.
Desta Z, Zhao X, Shin JG, et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41:12.
Sim S, Risinger C, Dahl ML, et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006;79:103–13.
Wedlund PJ. The CYP2C19 enzyme polymorphism. Pharmacology. 2000;61(3):174–83.
Ford N. Clopidogrel resistance: pharmacokinetic or pharmacogenetic? J Clin Pharmacol. 2009;49(5):506–12.
Hulot JS, Bura A, Villard E, et al. Cytochrome P450 2C19 loss-of function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006;108(7):2244–7.
Shuldiner A, O’Connell J, Bliden K, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA. 2009;302(8):849–57.
Norgard N, Mathews K, Wall G. Drug-drug interactions between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009;43:1266–74.
Shimatani T, Inoue M, Kuroiwa T, et al. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: A crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19. Clin Pharmacol Ther. 2006;79:144–52.
Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics. 2001;11:341–8.
Furuta T, Shirai N, Takashima M, et al. Effect of genotypic differences in CYP2C19 on cure rates for Helicobacter pylori infection by triple therapy with a proton pump inhibitor, amoxicillin, and clarithromycin. Clin Pharmacol Ther. 2001;69:158–68.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media New York
About this chapter
Cite this chapter
Jericho, B., Aguiar, A., Dull, R.O. (2015). CYP2C19: The Support Crew II. In: Marcucci, C., et al. A Case Approach to Perioperative Drug-Drug Interactions. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7495-1_11
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7495-1_11
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7494-4
Online ISBN: 978-1-4614-7495-1
eBook Packages: MedicineMedicine (R0)